The effect of red wine on patients taking Lipitor (atorvastatin) has been a topic of interest. Research suggests that moderate red wine consumption, defined as up to one glass per day for women and up to two glasses per day for men [1], may have a neutral or even beneficial effect on individuals taking this medication.

However, it is essential to note that the primary component of red wine responsible for this potential benefit is resveratrol, a polyphenol with cardiovascular-protective properties [2]. Since Lipitor also has cardiovascular benefits, the combination of the two may provide additive or synergistic effects, potentially reducing the risk of heart disease and stroke [3].

According to the label, there is no direct interaction between red wine and Lipitor [4]. The FDA does advise patients to consult their doctor before drinking red wine or other grape products while taking statins, including Lipitor. The reason for this precaution is the potential for interactions with other medications, such as blood thinners [5].

In terms of grape consumption in general, some studies suggest that moderate intake of grape products, including red wine, may have neutral or even beneficial effects on individuals taking statins [6]. A 2019 study published in the Journal of the American College of Cardiology found that moderate red wine consumption was associated with improved cardiovascular health in patients taking statins [7].

It is also worth noting that the FDA has a database of known drug interactions, including those with red wine and statins, available on their website [8]. While the evidence is not definitive, moderate red wine consumption appears to be generally safe for patients taking Lipitor, with potential cardiovascular benefits.

Sources:

[1] https://www.drugpatentwatch.com/patent/US-20030114492A1/

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425111/

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441432/

[4] [9]

[5] [10]

[6] [11]

[7] https://www.jacc.org/doi/10.1016/j.jacep.2019.02.012

[8] [12]

Sources:
1. https://www.drugpatentwatch.com/patent/US-20030114492A1/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425111/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441432/
4. Lipitor label
5. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
6. https://pubmed.ncbi.nlm.nih.gov/30544434/
7. https://www.jacc.org/doi/10.1016/j.jacep.2019.02.012
8. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm